UltraProteins for Human Health

MISSION

Protuoso integrates machine learning with computational protein design and synthetic biology to engineer multifunctional UltraProteins for biomedical applications.

TEAM

We are protein engineering virtuosos, drug developers, and entrepreneurs seeking to transform the treatment of complex diseases with UltraProteins that can overcome the inherent complexity of human diseases.

THE CHALLENGE

Complex diseases require complex interventions. Tackling complex diseases, such as cancer, inflammation, neurodegeneration, and obesity, requires a combination of drugs that act on different targets within interconnected regulatory networks. However, administering a cocktail of individual drugs faces significant manufacturing, delivery, and regulatory hurdles, as well as clinical risks. The all-in-one format of multifunctional proteins dramatically simplifies this cumbersome process. However, multifunctional proteins are difficult to engineer because of the nearly infinite design space and the fact that protein function often changes in unpredictable ways when introducing greater complexity.

THE ULTRAPROTEIN DESIGN HYPERLOOP

Protuoso has developed a universal platform to design multifunctional UltraProteins composed of multiple distinct functional modules that execute complex biological tasks, such as treating multifactorial diseases or enabling novel biotechnology applications. Protuoso’s UltraProtein Design Hyperloop integrates the power of generative AI, computational protein design, and synthetic biology to achieve efficient and high-throughput UltraProtein design-build-test-learn. Leveraging the UltraProtein Design Hyperloop, Protuoso executes a lean operational model with a capital-efficient corporate structure to enable diversified strategic partnerships. With these advantages, Protuoso aims to become a perpetual engine to generate and monetize UltraProtein assets across the biotechnology field.

PARTNERING

Partnering is integral to our business model and we welcome interested parties with any biomedical application that they wish to address with more powerful proteins to reach out.